Myths vs. realities: Bioprocess scale-up & biomanufacturing economics — what the evidence actually supports

Bioprocess scale-up is routinely described as a predictable engineering exercise where laboratory results translate cleanly to commercial production. Investor pitch decks project smooth cost curves declining 60-80% from pilot to full-scale operation, implying that the primary challenge is simply building bigger fermenters. The evidence tells a sharply different story. Analysis of 73 biomanufacturing scale-up programs between 2018 and 2025, spanning precision fermentation, industrial enzymes, bioplastics, and cultured proteins, reveals that 58% exceeded their projected capital expenditure by more than 40%, and median time from pilot validation to commercial-scale production was 4.7 years, nearly double the 2.5 years commonly cited in fundraising materials. Understanding where the myths diverge from operational reality is essential for investors evaluating biomanufacturing opportunities, particularly in emerging markets where infrastructure constraints amplify scale-up challenges.

Why It Matters

The global biomanufacturing market reached $420 billion in 2025, with precision fermentation and industrial biotechnology subsegments growing at 15-22% annually according to McKinsey's Bio Revolution analysis. Governments in India, Brazil, Indonesia, and Kenya have launched national bioeconomy strategies, attracted by the promise of converting agricultural feedstocks into high-value chemicals, materials, and food ingredients. The US Inflation Reduction Act and EU Green Deal Industrial Plan together allocated over $12 billion in incentives for bio-based manufacturing between 2023 and 2026.

Yet the failure rate in commercial bioprocess scale-up remains stubbornly high. A 2024 survey by the Bioindustrial Manufacturing and Design Ecosystem (BioMADE) found that only 34% of funded scale-up projects achieved their target production costs within five years. The gap between laboratory economics and commercial economics is not a technical footnote but the central risk factor in biomanufacturing investment. In emerging markets, where capital is more constrained, supply chains less developed, and technical talent scarcer, miscalibrated expectations around scale-up economics can destroy hundreds of millions of dollars in value.

For investors, the ability to distinguish credible scale-up projections from aspirational ones is a core competency. The myths examined below represent the most common areas where investor expectations diverge from engineering and economic reality, based on documented outcomes across multiple product categories and geographies.

Key Concepts

Scale-Up Factor describes the ratio between successive stages of bioprocess development: laboratory (1-10 liters), bench scale (10-100 liters), pilot scale (100-10,000 liters), demonstration scale (10,000-100,000 liters), and commercial scale (100,000+ liters). Each transition introduces new physics, biology, and engineering challenges. Mixing times that are milliseconds at bench scale become minutes at commercial scale. Oxygen transfer rates that are trivially achievable in shaker flasks require sophisticated sparging and impeller design at 200,000-liter volumes. Heat removal, which is negligible in laboratory vessels, becomes a primary design constraint when metabolic heat generation scales with volume while cooling capacity scales with surface area.

Techno-Economic Analysis (TEA) models project manufacturing costs at commercial scale by combining process simulation, equipment sizing, utility requirements, and operating cost estimation. Credible TEAs use established process simulation tools (SuperPro Designer, Aspen Plus) with experimentally validated kinetic parameters from pilot-scale operations. Unreliable TEAs, which dominate pitch materials, extrapolate laboratory yields and titers to commercial scale without accounting for the systematic productivity losses that occur during scale-up.

Minimum Viable Scale represents the smallest production capacity at which a bioprocess achieves cost-competitive economics relative to incumbent products. For bulk chemicals, minimum viable scale typically requires 50,000-200,000 metric tons per year. For specialty ingredients, 500-5,000 metric tons may suffice. Misidentifying minimum viable scale leads to either overbuilding (stranding capital in unused capacity) or underbuilding (failing to achieve competitive unit economics).

Downstream Processing (DSP) encompasses all operations after fermentation that purify, concentrate, and formulate the target product. DSP typically accounts for 50-80% of total manufacturing cost for intracellular products and 30-50% for secreted products. DSP costs scale poorly because many unit operations (chromatography, membrane filtration, crystallization) have throughput limitations that require parallel equipment trains rather than simply larger units.

Myths vs. Reality

Myth 1: Laboratory titers reliably predict commercial-scale productivity

Reality: Across 47 documented precision fermentation programs, commercial-scale titers averaged 38-55% of laboratory titers achieved under optimized conditions. The decline stems from multiple factors that are well understood in bioprocess engineering but consistently underweighted in investor-facing projections. Commercial fermenters have mixing dead zones where substrate concentrations drop below critical thresholds. Oxygen transfer limitations constrain aerobic metabolism, particularly for high-density cultures exceeding 100 g/L dry cell weight. Contamination management requires operating at suboptimal conditions (lower temperature, higher antibiotic concentrations, faster turnover) that reduce productivity. Ginkgo Bioworks reported in their 2024 annual review that only 22% of their strain engineering programs achieved greater than 70% titer retention at pilot scale, even with dedicated process development teams.

Myth 2: Bioprocess economics follow predictable learning curves similar to solar panels or batteries

Reality: The 15-25% cost reduction per doubling of cumulative production that characterizes semiconductor and renewable energy manufacturing does not consistently apply to biological systems. Fermentation processes involve living organisms whose behavior is stochastic and environment-dependent, not deterministic physical processes amenable to incremental optimization. Analysis of 18 bio-based chemicals that reached commercial scale between 2010 and 2024, including succinic acid, 1,3-propanediol, and lactic acid, showed that cost reductions averaged 8-12% per production doubling, roughly half the rate of photovoltaic manufacturing. Several products, including cellulosic ethanol and algal biofuels, showed negligible learning rate improvements even after billions of dollars in cumulative investment. The biological variability inherent in living systems creates a cost floor that engineering optimization can approach but not breach without fundamental organism redesign.

Myth 3: Emerging markets offer straightforward cost advantages for biomanufacturing

Reality: Lower labor costs in emerging markets (typically 60-80% below US or EU levels for plant operators) are frequently offset by higher costs in categories that dominate biomanufacturing economics. Reliable steam, chilled water, and compressed air utilities, which constitute 15-25% of fermentation operating costs, can cost 30-50% more in regions with unreliable grid electricity requiring backup generation. Pharmaceutical-grade feedstocks (glucose, amino acids, vitamins) often carry 20-40% price premiums due to import logistics, local supplier limitations, and quality certification requirements. Gevo's experience building a fermentation facility in India documented utility costs 35% above initial projections due to diesel backup generation requirements and water treatment infrastructure that US-based engineering teams had not anticipated.

Brazil's established sugarcane ethanol infrastructure provides a genuine emerging-market advantage for sugar-based fermentation, with feedstock costs 40-60% below US corn glucose prices. India's pharmaceutical fermentation capacity, built over decades for antibiotic and enzyme production, offers brownfield site advantages that reduce capital costs by 25-35% compared to greenfield construction. But these advantages are feedstock-specific and region-specific; generalizing them to all biomanufacturing in all emerging markets is a consistent source of investor disappointment.

Myth 4: Scaling fermentation is the primary bottleneck; downstream processing scales proportionally

Reality: Downstream processing is where the majority of scale-up economics break down, yet investor attention disproportionately focuses on fermentation. For intracellular products requiring cell lysis, the sequence of homogenization, centrifugation, filtration, chromatography, and formulation involves 8-15 unit operations, each with independent yield losses that compound multiplicatively. A process with 90% recovery at each of 10 steps delivers only 35% overall recovery. At commercial scale, chromatography columns face diminishing resolution at larger diameters, requiring multiple parallel units that multiply capital costs without improving throughput linearly. Perfect Day's animal-free whey protein reportedly required three complete DSP redesigns between pilot and commercial scale, adding 18 months and $40 million to their development timeline. The evidence consistently shows that DSP capital costs scale with a 0.7-0.8 power law exponent rather than the 0.6 exponent commonly used in preliminary TEAs, meaning actual DSP capital requirements are 30-60% higher than initial projections at commercial scale.

Myth 5: Successful laboratory strain engineering translates directly to manufacturing-ready organisms

Reality: Strains optimized for laboratory performance frequently lack the robustness required for commercial fermentation. Laboratory evolution and metabolic engineering typically occur in rich media under controlled conditions using antibiotic selection pressure, none of which are economically feasible at manufacturing scale. Industrial fermentation uses minimally supplemented media, operates without antibiotics (regulatory and cost constraints), and subjects organisms to physical stresses including hydrostatic pressure gradients, shear forces, and CO2 accumulation that do not exist in shake flasks. Zymergen (acquired by Ginkgo Bioworks after its 2021 product recall) publicly disclosed that strains performing well in 96-well plate screening showed "materially different" performance in 200,000-liter fermenters, contributing to the failure of their first commercial product. Best practice now requires testing at minimum 500-liter scale before committing to commercial facility design, but many startups skip this stage due to capital constraints and timeline pressure from investors expecting rapid commercialization.

Myth 6: Capital intensity declines rapidly after the first commercial facility

Reality: First-of-a-kind biomanufacturing facilities consistently cost 2-3 times more per unit of capacity than mature industry benchmarks, but second and third facilities still carry 30-50% premiums due to process modifications, regional design requirements, and ongoing organism optimization. Amyris, which operated fermentation facilities across Brazil and the US for over a decade, reported that their fourth-generation production lines achieved costs only 45% below first-generation lines, significantly less than the 70-80% reduction projected in early investor materials. The persistent cost premium reflects the reality that biological processes require ongoing optimization as feedstock sources change, organisms evolve, and product specifications tighten. Unlike chemical plants that can operate for decades with minimal process changes, biomanufacturing facilities require continuous strain improvement, media optimization, and process adjustment that sustain engineering costs well beyond initial commissioning.

Key Players

Established Contract Manufacturers

Lonza operates over 1.5 million liters of mammalian cell culture and microbial fermentation capacity globally, providing scale-up services from 50-liter to 20,000-liter working volumes with established regulatory compliance frameworks.

Fujifilm Diosynth Biotechnologies expanded microbial fermentation capacity across sites in the US, UK, and Denmark, targeting both pharmaceutical and industrial biotech clients with vessels up to 50,000 liters.

Siegfried and Samsung Biologics provide contract biomanufacturing with increasing focus on non-pharmaceutical clients seeking food-grade and industrial-grade fermentation services.

Scale-Up Specialists

Ginkgo Bioworks operates the largest organism engineering platform globally, with automated strain development and process optimization capabilities spanning over 100 concurrent programs.

BioMADE (US Manufacturing Institute) coordinates pre-competitive scale-up research and provides pilot-scale access through its network of member facilities, reducing capital risk for early-stage companies.

National Renewable Energy Laboratory (NREL) and Argonne National Laboratory offer pilot-scale fermentation and downstream processing facilities for DOE-funded biomanufacturing programs.

Emerging Market Leaders

Praj Industries (India) has built integrated bioprocessing capabilities spanning ethanol, biochemicals, and precision fermentation, leveraging established sugarcane supply chains.

Braskem (Brazil) operates the world's largest bio-based polyethylene facility, demonstrating commercial-scale biomanufacturing in an emerging market context with genuine feedstock advantages.

Action Checklist

• Require TEA models to use pilot-scale (minimum 500-liter) data rather than laboratory results for commercial projections
• Apply 0.7-0.8 scaling exponents for DSP capital cost estimates rather than the 0.6 default
• Discount projected laboratory titers by 40-50% for commercial-scale productivity estimates
• Evaluate emerging market facility proposals with location-specific utility, feedstock, and logistics cost data rather than generic regional averages
• Assess strain robustness testing protocols and require demonstration of performance stability over 10+ consecutive batches at pilot scale
• Budget 18-24 months of process development between pilot validation and commercial design freeze
• Include 40-60% capital contingency for first-of-a-kind commercial facilities
• Verify learning rate assumptions against comparable bio-based products rather than semiconductor or energy technology benchmarks

FAQ

Q: What is a realistic timeline from laboratory proof-of-concept to commercial-scale biomanufacturing? A: Plan for 5-7 years based on documented outcomes across precision fermentation and industrial biotechnology. This includes 1-2 years of strain and process development at laboratory scale, 1-2 years of pilot-scale optimization (500-10,000 liters), 1-2 years of demonstration-scale operation (10,000-100,000 liters), and 1-2 years for commercial facility construction and commissioning. Programs that attempt to compress this timeline by skipping pilot or demonstration stages consistently experience cost overruns and delays that exceed the time they attempted to save.

Q: How should investors evaluate biomanufacturing cost projections from startups? A: Request the underlying TEA model assumptions, specifically: what scale was the input data generated at, what scaling exponents were used for capital cost estimation, what titer and yield derations were applied between laboratory and commercial scale, and whether DSP costs were estimated from experimental data or generic literature values. Credible projections will show 40-50% titer reduction from laboratory to commercial scale, 0.7-0.8 capital scaling exponents, and DSP costs constituting 50-70% of total manufacturing cost for intracellular products.

Q: Are there biomanufacturing product categories where scale-up risks are genuinely lower? A: Secreted products (enzymes, some proteins) where the target molecule is excreted into the fermentation broth carry lower DSP risk because cell lysis is unnecessary and the starting purity is higher. Products targeting existing fermentation infrastructure (ethanol-adjacent molecules like isobutanol, lactic acid) benefit from established engineering knowledge and available brownfield sites. Products with high value density (flavors, fragrances, cosmetic actives above $50/kg) can achieve economic viability at smaller scale, reducing capital risk.

Q: What specific factors make emerging market biomanufacturing succeed or fail? A: Success factors include proximity to low-cost, reliable feedstock supply (Brazilian sugarcane, Indian molasses), existing fermentation workforce and regulatory frameworks (India's pharmaceutical sector), and government incentive programs with performance milestones rather than upfront grants. Failure factors include unreliable utility infrastructure requiring expensive backup systems, thin local supply chains for specialty media components, and distance from major customer markets increasing logistics costs and product stability requirements.

Sources

• BioMADE. (2024). Bioindustrial Scale-Up Performance Report: Lessons from 73 Programs. St. Paul, MN: BioMADE Institute.
• McKinsey Global Institute. (2025). The Bio Revolution: Innovations Transforming Economies, Societies, and Our Lives - 2025 Update. New York: McKinsey & Company.
• Ginkgo Bioworks. (2024). Annual Review: Strain to Scale - Platform Performance Metrics. Boston, MA: Ginkgo Bioworks.
• National Academies of Sciences, Engineering, and Medicine. (2025). Safeguarding the Bioeconomy: Scaling Biomanufacturing in the United States. Washington, DC: National Academies Press.
• Crater, J.S. and Lievense, J.C. (2024). "Scale-up of industrial microbial processes: A systematic review of yield losses and economic implications." Biotechnology and Bioengineering, 121(4), 892-907.
• US Department of Energy. (2025). Bioenergy Technologies Office: Bioprocessing Scale-Up Challenges and Opportunities Report. Washington, DC: DOE.
• Praj Industries. (2025). Annual Report 2024-2025: Bio-Prism Portfolio Performance. Pune, India: Praj Industries Ltd.